RU2696892C2 - САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII - Google Patents

САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII Download PDF

Info

Publication number
RU2696892C2
RU2696892C2 RU2016106577A RU2016106577A RU2696892C2 RU 2696892 C2 RU2696892 C2 RU 2696892C2 RU 2016106577 A RU2016106577 A RU 2016106577A RU 2016106577 A RU2016106577 A RU 2016106577A RU 2696892 C2 RU2696892 C2 RU 2696892C2
Authority
RU
Russia
Prior art keywords
egfrviii
seq
binding
binding protein
cells
Prior art date
Application number
RU2016106577A
Other languages
English (en)
Russian (ru)
Other versions
RU2016106577A (ru
Inventor
Кристина ЭЛЛВАНГЕР
Уве РОЙШ
Ивица ФУЦЕК
Стефан КНАКМУС
Вера МОЛКЕНТИН
Мелвин ЛИТЛ
Евгений ЖУКОВСКИ
Original Assignee
Аффимед Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аффимед Гмбх filed Critical Аффимед Гмбх
Publication of RU2016106577A publication Critical patent/RU2016106577A/ru
Application granted granted Critical
Publication of RU2696892C2 publication Critical patent/RU2696892C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2016106577A 2013-08-07 2014-08-07 САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII RU2696892C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13179630 2013-08-07
EP13179630.2 2013-08-07
EP13189599 2013-10-21
EP13189599.7 2013-10-21
PCT/EP2014/002177 WO2015018527A1 (en) 2013-08-07 2014-08-07 ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII

Publications (2)

Publication Number Publication Date
RU2016106577A RU2016106577A (ru) 2017-09-14
RU2696892C2 true RU2696892C2 (ru) 2019-08-07

Family

ID=51453717

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016106577A RU2696892C2 (ru) 2013-08-07 2014-08-07 САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII

Country Status (13)

Country Link
US (1) US10273309B2 (enExample)
EP (1) EP3030581B1 (enExample)
JP (1) JP6529498B2 (enExample)
CN (1) CN105555804B (enExample)
AU (1) AU2014304930B2 (enExample)
CA (1) CA2920173C (enExample)
DK (1) DK3030581T3 (enExample)
HR (1) HRP20210561T1 (enExample)
HU (1) HUE054057T2 (enExample)
LT (1) LT3030581T (enExample)
RU (1) RU2696892C2 (enExample)
SI (1) SI3030581T1 (enExample)
WO (1) WO2015018527A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY178160A (en) * 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
CN107108735B (zh) * 2014-11-25 2021-05-04 药物抗体公司 新型egfrviii抗体和包含所述抗体的组合物
EP4190814A1 (en) 2015-05-29 2023-06-07 Amphivena Therapeutics, Inc. Methods of using bispecific cd33 and cd3 binding proteins
EP3307319A4 (en) 2015-06-09 2019-05-22 Memorial Sloan Kettering Cancer Center T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA
WO2016204966A1 (en) * 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EP3405481B1 (en) 2016-01-21 2023-01-18 Pfizer Inc. Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
CN109219618B (zh) * 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
CA3011942A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
RU2721582C1 (ru) * 2016-08-05 2020-05-20 И-Байолоджикс Инк. Антитела против лиганда-1 запрограммированной смерти (PD-L1) и их применение
AU2017306506B2 (en) 2016-08-05 2020-05-21 Y-Biologics Inc. Antibody to programmed cell death 1 (PD-1) and use thereof
CN106501518A (zh) * 2017-01-06 2017-03-15 北京弘润天源生物技术股份有限公司 一种检测EGFRvⅢ的免疫组化抗体试剂及检测方法
CA3051062C (en) * 2017-02-28 2023-09-26 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
KR102924742B1 (ko) * 2018-03-14 2026-02-10 아피메트 게엠베하 이중특이적 egfr/cd16 항원-결합 단백질
CN118271445A (zh) * 2018-12-21 2024-07-02 豪夫迈·罗氏有限公司 与cd3结合的抗体
AU2020208110A1 (en) * 2019-01-14 2021-07-15 Nanjing Legend Biotech Co., Ltd. Chimeric receptor polypeptides and uses thereof
BR112022011357A2 (pt) 2019-12-13 2022-08-23 Genentech Inc Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
WO2022002033A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 具有H2L2与HCAb结构的结合蛋白
US20240101646A1 (en) * 2021-01-22 2024-03-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
EP4370557A4 (en) * 2021-07-16 2025-10-01 Medical Guidance Systems Llc TAX-INTERACTING PROTEIN-BINDING MOLECULES 1 (TIP1)
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2317999C2 (ru) * 2000-02-25 2008-02-27 Те Гавернмент Оф Те Юнайтед Стейтс, Эз Репризентед Бай Те Секретари Оф Те Департмент Оф Хелт Энд Хьюман Сервисез SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2457586A1 (en) * 2003-06-27 2012-05-30 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2317999C2 (ru) * 2000-02-25 2008-02-27 Те Гавернмент Оф Те Юнайтед Стейтс, Эз Репризентед Бай Те Секретари Оф Те Департмент Оф Хелт Энд Хьюман Сервисез SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2457586A1 (en) * 2003-06-27 2012-05-30 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOI B.D. et al., Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma, PNAS, 2013, vol. 110, no. 1, p.270-275. *

Also Published As

Publication number Publication date
CN105555804A (zh) 2016-05-04
EP3030581B1 (en) 2021-01-20
AU2014304930A1 (en) 2016-02-25
HK1218552A1 (zh) 2017-02-24
EP3030581A1 (en) 2016-06-15
HUE054057T2 (hu) 2021-08-30
CA2920173A1 (en) 2015-02-12
JP2016536322A (ja) 2016-11-24
BR112016002610A2 (pt) 2017-09-12
CN105555804B (zh) 2020-12-25
AU2014304930B2 (en) 2019-11-21
HRP20210561T1 (hr) 2021-05-14
US20160152728A1 (en) 2016-06-02
BR112016002610A8 (pt) 2018-01-23
RU2016106577A (ru) 2017-09-14
DK3030581T3 (da) 2021-04-12
SI3030581T1 (sl) 2021-07-30
JP6529498B2 (ja) 2019-06-12
CA2920173C (en) 2021-08-10
LT3030581T (lt) 2021-05-25
WO2015018527A1 (en) 2015-02-12
US10273309B2 (en) 2019-04-30

Similar Documents

Publication Publication Date Title
EP3030581B1 (en) Antibody binding sites specific for egfrviii
JP7411316B2 (ja) 三重特異性結合タンパク質と使用方法
US12202911B2 (en) Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
JP6907124B2 (ja) Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
EP3470426A1 (en) Multispecific antibody
KR20200104305A (ko) 삼중 사슬 항체(Triple-Chain Antibody)의 제조 방법 및 용도
US20240392003A1 (en) Multispecific antibodies having specificity for ror1 and cd3
US20230192861A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
TW201920282A (zh) 抗egfr和pd-1的雙特異性抗體
WO2023006040A1 (zh) 抗pvrig/抗tigit双特异性抗体和应用
JP2023526977A (ja) Ｃｄ４０結合タンパク質
KR20230154235A (ko) NKp46에 대한 항체 및 이의 적용
JP2022530496A (ja) Ｐｄ－１およびｌａｇ－３に対する二重特異性抗体
JP2024516748A (ja) ＥＧＦＲｖＩＩＩ結合タンパク質
WO2024165049A1 (zh) 抗cdh6的抗体及其用途
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
EP4574844A1 (en) Multispecific antibodies having specificity for cd47 and pdl1
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
WO2025040144A1 (zh) B7-h7抗原结合分子及其应用
HK1218552B (zh) 对egfrviii有特异性的抗体结合位点
BR112016002610B1 (pt) Anticorpo de ligação a locais específicos para egfrviii
NZ744187B2 (en) Therapeutic anti-cd9 antibody